Scilex Holding (SCLX) Shares Outstanding (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Shares Outstanding (Entity) of $6.9 million for Q1 2026, up 36.05% year-over-year from $5.1 million in Q1 2025, and up 62352.42% quarter-over-quarter from $11034.0 in Q4 2025.
Scilex Holding (SCLX) Shares Outstanding (2020 - 2026) Analysis & Trends
Scilex Holding's Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $6.9 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 36.05% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (up 36.05% YoY), while the FY2025 annual figure was $11034.0, down 99.71% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $6.9 million, up from $11034.0 in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $6.9 million in Q1 2026, with the low at $2926.0 in Q1 2024.
- The 5-year median for Shares Outstanding (Entity) is $492832.0 (2022), against an average of $2.2 million.
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) plunged 99.93% in 2024, then jumped 173003.21% in 2025.
- Scilex Holding's Shares Outstanding (Entity) stood at $3835.0 in 2022, then soared by 96969.47% to $3.7 million in 2023, then climbed by 0.64% to $3.7 million in 2024, then sank by 99.71% to $11034.0 in 2025, then surged by 62352.42% to $6.9 million in 2026.
- Business Quant data shows SCLX's Shares Outstanding (Entity) at $6.9 million in Q1 2026, $11034.0 in Q4 2025, and $11604.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.51 Bn | 632.75 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 470.18 Bn | 463.61 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 376.85 Bn | 369.71 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn | 1.91 Bn |
| 5 | Astrazeneca | 257.42 Bn | 252.52 Bn | 12.86 Bn | 1.55 Bn |
| 6 | Amgen | 236.70 Bn | 222.71 Bn | 7.24 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 182.16 Bn | 178.98 Bn | 6.22 Bn | 1.24 Bn |
| 8 | Pfizer | 159.30 Bn | 147.60 Bn | 10.94 Bn | 5.70 Bn |
| 9 | Gsk | 106.12 Bn | 101.95 Bn | 8.24 Bn | 2.03 Bn |
| 10 | Scilex Holding | 39.28 Mn | -73.51 Mn | 3.97 Mn | 6.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.89 Mn |
| Dec 31, 2025 | 11,034.00 |
| Sep 30, 2025 | 11,604.00 |
| Jun 30, 2025 | 11,595.00 |
| Mar 31, 2025 | 5.07 Mn |
| Dec 31, 2024 | 3.75 Mn |
| Sep 30, 2024 | 3,627.00 |
| Jun 30, 2024 | 3.24 Mn |
| Mar 31, 2024 | 2,926.00 |
| Dec 31, 2023 | 3.72 Mn |
| Sep 30, 2023 | 3.99 Mn |
| Jun 30, 2023 | 4.07 Mn |
| Mar 31, 2023 | 4.05 Mn |
| Dec 31, 2022 | 3,835.00 |
| Sep 30, 2022 | 376,450.00 |
| Jun 30, 2022 | 491,554.00 |
| Mar 31, 2022 | 492,832.00 |
| Dec 31, 2021 | 480,951.00 |
| Sep 30, 2021 | 492,832.00 |
| Jun 30, 2021 | 394,266.00 |